The FDA now allows some adults on Wegovy to escalate up to 7.2 mg once weekly. That does not mean everyone starting semaglutide should aim for the higher pen. The current label still treats 2.4 mg as the standard recommended maintenance dose for adult weight reduction. The 7.2 mg option is for adults who have already tolerated 2.4 mg for at least 4 weeks and still need more weight loss. [1] [2]
That is the key practical shift: Wegovy 7.2 mg is an escalation tool, not a new beginner dose, not a replacement for every 2.4 mg patient, and not a reason to ignore side effects that are already hard to manage. If you need the broader semaglutide background first, start with our complete semaglutide guide. If side effects are already the limiting factor, keep our GLP-1 side effects guide open while you read.
What FDA actually approved
The approved change is narrower than some headlines make it sound. For adult weight reduction, the current FDA label says Wegovy stays at 1.7 mg or 2.4 mg for maintenance, with 2.4 mg recommended for most adults. The new piece is this: if a patient has tolerated 2.4 mg once weekly for at least 4 weeks and additional weight reduction is clinically indicated, the dose may be increased to 7.2 mg once weekly. [1]
Important limits:
- this escalation language applies to adults, not pediatric patients
- it applies to weight reduction, not to a separate cardiovascular-risk dose track
- it is still Wegovy used alongside reduced-calorie diet and increased physical activity
- it is not approved to be used with another semaglutide product or another GLP-1 receptor agonist [1] [2]
So the cleanest answer to “Who is Wegovy 7.2 mg for?” is: adults who are already doing reasonably well on Wegovy 2.4 mg, are tolerating it, and still have a strong clinical case for trying to push weight loss further.
How it differs from prior Wegovy dosing
Before this update, most Wegovy conversations ended at 2.4 mg once weekly. That remains the core maintenance target and the dose most people will still hear about first. The new 7.2 mg pen creates a second adult maintenance tier above that baseline. [1] [2]
This does not change the front half of the schedule. Patients still start low and titrate gradually:
| Weeks | Wegovy injection dose |
|---|---|
| 1-4 | 0.25 mg weekly |
| 5-8 | 0.5 mg weekly |
| 9-12 | 1 mg weekly |
| 13-16 | 1.7 mg weekly |
| 17 onward | 2.4 mg weekly for most adults |
| After at least 4 weeks on 2.4 mg, if still indicated | Consider 7.2 mg weekly |
That last row is the change. It matters because it turns Wegovy from a single ceiling into a more flexible adult obesity pathway. But it also means the higher dose is only sensible if the patient has already shown they can live with semaglutide at 2.4 mg in real life, not just in theory. [1]
What efficacy expectations are reasonable
The strongest practical message is this: 7.2 mg appears meaningfully stronger than older Wegovy expectations, but it is not a magic reset button.
Novo Nordisk’s official HCP summary of STEP UP describes a 72-week trial of 1,407 adults with obesity without diabetes. On the company’s reported efficacy estimand, Wegovy HD 7.2 mg produced 20.7% mean weight loss versus 2.4% with placebo. On the treatment-regimen estimand, which is closer to what many people care about in practice because it includes treatment discontinuation, the reported mean loss was 18.8% versus 3.9% with placebo. The same page reports that 88.7% of participants on 7.2 mg achieved at least 5% weight loss, versus 38.3% on placebo. [4] [5]
That is a real step up from the older STEP 1 benchmark, where semaglutide 2.4 mg produced 14.9% mean weight loss at 68 weeks versus 2.4% with placebo. [6]
The right way to interpret that difference is not “everyone should rush to 7.2 mg.” It is:
- the higher dose may help some adults who have plateaued at 2.4 mg
- the extra benefit is only useful if the patient can stay on the dose
- the most realistic expectation is incremental improvement, not automatic transformation
If someone is already losing steadily, functioning well, and protecting muscle mass with adequate protein and resistance training, the extra upside may be worth a conversation. If someone is barely hanging on because of nausea or dehydration, the higher efficacy ceiling may not matter much if adherence collapses.
What side effects may change
This is where the article needs to be blunt. The label does not present 7.2 mg as a cleaner version of Wegovy. It presents it as a stronger version that can also bring more adverse effects. [2]
In the adult obesity studies summarized in the current label and DailyMed listing:
| Adverse reaction | Placebo | Wegovy 2.4 mg | Wegovy 7.2 mg |
|---|---|---|---|
| Nausea | 13% | 35% | 39% |
| Vomiting | 6% | 16% | 22% |
| Dysesthesia | 0% | 6% | 22% |
| Constipation | 8% | 19% | 20% |
| Hair loss | 1% | 3% | 6% |
The most eye-catching number there is dysesthesia. That umbrella term includes altered skin sensations such as burning, tingling, increased sensitivity, or discomfort. It was reported much more often at 7.2 mg than at 2.4 mg in the adult obesity trials summarized in the label materials. [2] [3]
That does not mean every patient will feel it. It does mean this is not just a “slightly more nausea” conversation. The higher dose may bring a different symptom mix, and that is exactly the kind of tradeoff worth discussing before escalation.
If you are already dealing with nausea, reflux, constipation, dizziness, dehydration, or reduced oral intake at 2.4 mg, moving higher without a serious tolerability discussion is not a smart shortcut. Review our side-effects guide if you need a framework for tracking what is normal versus what deserves a call to your prescriber.
Who should consider escalating and who should pause
Adults who may be reasonable candidates
- people who have tolerated 2.4 mg well for at least 4 weeks
- people who are still losing too slowly for their clinical goals or have clearly plateaued
- people whose clinician believes the likely extra benefit outweighs the higher side-effect risk
Adults who should slow down and reassess first
- anyone with meaningful nausea, vomiting, dehydration, constipation, or poor oral intake on 2.4 mg
- anyone who has started skipping doses because tolerability is already shaky
- anyone expecting the higher dose to fix a plateau caused mainly by inconsistent intake, inconsistent use, or unrealistic time expectations
There is also a special conversation for people with type 2 diabetes. The Wegovy label says blood glucose should be monitored before and during treatment in patients with diabetes. If diabetes medications, appetite changes, and faster weight loss are all moving at once, escalation deserves more supervision, not less. [1] [2]
Questions to ask a clinician before moving up
Use this short list at the appointment:
| Ask this | Why it matters |
|---|---|
| Am I actually tolerating 2.4 mg well enough to justify escalation? | The label only makes sense here if 2.4 mg is already livable. |
| What extra weight loss is realistic for me, not just in trial averages? | Trial averages are not personal guarantees. |
| Which side effects would make you want me to stay put, delay, or step back down? | You want the stop rules before symptoms start. |
| If I have diabetes or take insulin or a sulfonylurea, what should I watch with glucose? | Semaglutide can change intake and glucose patterns. |
| How will we decide whether 7.2 mg is working well enough to keep? | Escalation should have a review point, not run on autopilot. |
That last question matters more than it sounds. The biggest mistake with higher-dose obesity medication is often not the prescription itself. It is drifting upward without a clear plan for what success, failure, or unacceptable side effects actually look like.
Bottom line
Wegovy 7.2 mg is a meaningful label update, but it is not a universal new destination. FDA’s current language makes it an adult-only escalation option after successful tolerance of 2.4 mg, for cases where additional weight reduction is still clinically indicated. [1] [2]
The upside is real: the available STEP UP results suggest stronger average weight loss than older Wegovy expectations anchored in STEP 1. [4] [5] [6]
The catch is also real: side effects may rise, and some symptoms, especially altered skin sensations, appear notably more common at the higher dose. [2] [3]
If you want the short rule, use this one: 7.2 mg is for adults who are tolerating 2.4 mg, still need more help, and have a clinician who agrees the likely benefit is worth the extra risk. Everyone else should treat it as an option to evaluate carefully, not a badge of progress.
